Prostate Cancer - Results from #440

PSA Levels and Mortality in Prostate Cancer Patients. August 6, 2024

Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer. August 6, 2024

Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer. August 6, 2024

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies. August 6, 2024

Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. August 6, 2024

De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium. August 5, 2024

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. August 5, 2024

Salvage treatments after focal therapy for prostate cancer - a comprehensive review. August 5, 2024

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review. August 5, 2024

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). August 5, 2024

Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. August 5, 2024

Incidence and Pitfalls of Adipose Tissue Encountered in Prostatic Transurethral Resections and Related Specimens. August 5, 2024

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. August 5, 2024

LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer. August 5, 2024

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. August 5, 2024

Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. August 2, 2024

The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area. August 2, 2024

Artificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy. August 2, 2024

Antiandrogen Withdrawal Syndrome After Discontinuation of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer: A Report of Two Clinical Cases and a Literature Review. August 2, 2024

Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer. August 2, 2024

Page 23 of 1435